1. bookVolume 28 (2015): Issue 3 (September 2015)
Journal Details
License
Format
Journal
eISSN
2300-6676
First Published
30 May 2014
Publication timeframe
4 times per year
Languages
English
Open Access

Flozins, inhibitors of type 2 renal sodium-glucose co-transporter – not only antihyperglycemic drugs

Published Online: 26 Nov 2015
Volume & Issue: Volume 28 (2015) - Issue 3 (September 2015)
Page range: 155 - 158
Received: 17 Jun 2015
Accepted: 14 Aug 2015
Journal Details
License
Format
Journal
eISSN
2300-6676
First Published
30 May 2014
Publication timeframe
4 times per year
Languages
English

1. Bhatia K. et al.: Canagliflozin-current status in the treatment of type 2 diabetes mellitus with focus on clinical trial data. World J. Diabetes, 5, 399, 2014.10.4239/wjd.v5.i3.399405874524936262Search in Google Scholar

2. Chao E., Henry R.: SGLT2 inhibition - a novel strategy for diabetes treatment. Nature Rev. Drug Discov., 9, 551, 2010.Search in Google Scholar

3. Diamant M., Morsink L.: SGLT2 inhibitors for diabetes: turning symptoms into therapy. Lancet, 382, 917, 2013.Search in Google Scholar

4. Endocrine Today. http://www.healio.com/endocrinology/diabetes/(...)sglt2-inhibitors. (accessed 15.06.2014).Search in Google Scholar

5. Grandy S. et al.: Health-related quality of life (EQ-5D) among type 2 diabetes mellitus patients treated with dapagliflozin over 2 years. Int. J. Clin. Pract., 68, 486, 2014.10.1111/ijcp.1234124499168Search in Google Scholar

6. Henry R. et al.: Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomized controlled trial. Int. J. Clin. Pract., 66, 446, 2012.Search in Google Scholar

7. Jabbour S. et al.: Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study. Diabetes Care, 37, 740, 2014.10.2337/dc13-046724144654Search in Google Scholar

8. Ji L. et al.: Dapagliflozin as monotherapy in drug-naïve Asian patients with type 2 diabetes: a randomized, blinded, prospective phase III study. Clin. Ther., 36, 84, 2014.10.1016/j.clinthera.2013.11.00224378206Search in Google Scholar

9. Kaku K. et al.: Efficacy and safety of dapagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled with diet and exercise. Diabetes Obes. Metab., 16, 1102, 2014.10.1111/dom.1232524909293Search in Google Scholar

10. Kim G., Chung S.: Clinical implication of SGLT2 inhibitors in type 2 diabetes. Arch Pharm. Res., 37, 957, 2014.Search in Google Scholar

11. Kirk R.: Diabetes: Efficacy of dapagliflozin associated with renal function. Nat. Rev. Nephrol., 9, 695, 2013.10.1038/nrneph.2013.21624126593Search in Google Scholar

12. Kohan D. et al: Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int., 85, 962, 2014.10.1038/ki.2013.356397303824067431Search in Google Scholar

13. Kokot F., Hyla-Klekot L.: Nowe potencjalne tarcze ataku farmakologicznego w cukrzycy typu 2. Nefrol. Dializoter. Pol., 15, 239, 2011.Search in Google Scholar

14. Nauck M. et al.: Durability of glycaemic efficacy over 2 years with dapagliflozin, versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus was inadequately controlled with metformin. Diabetes Obes. Metab., 16, 1111, 2014.10.1111/dom.1232724919526Search in Google Scholar

15. Neal B. et al.: Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)--a randomized placebo-controlled trial. Am. Heart J., 166, 217, 2013.Search in Google Scholar

16. Nicolle L. et al.: Urinary tract infection in randomized phase III studies of canagliflozin, a sodium glucose co-transporter 2 inhibitor. Postgrad. Med., 126, 7, 2014.10.3810/pgm.2014.01.272024393747Search in Google Scholar

17. Plosker G.: Canagliflozin: a review of its use in patients with type 2 diabetes mellitus. Drugs, 74, 807, 2014.10.1007/s40265-014-0225-524831734Search in Google Scholar

18. Reilly T. et al.: Carcinogenicity risk assessment supports the chronic safety of dapagliflozin, an inhibitor of Sodium-Glucose Co-Transporter 2, in the treatment of type 2 diabetes mellitus. Diabetes Ther., 5, 73, 2014.10.1007/s13300-014-0053-3406528724474422Search in Google Scholar

19. Scheen A.: Evaluating SGLT2 inhibitors for type 2 diabetes: pharmacokinetic and toxicological considerations. Expert. Opin. Drug. Metab. Toxicol., 10, 647, 2014.10.1517/17425255.2014.87378824387329Search in Google Scholar

20. Strojek K. et al.: Dapagliflozin added to glimepiride in patients with type 2 diabetes mellitus sustains glycemic control and weight loss over 48 weeks: a randomized, double-blind, parallel-group, placebocontrolled trial. Diabetes Ther., 5, 267, 2014.10.1007/s13300-014-0072-0406528924920277Search in Google Scholar

21. Wilding J. et al.: Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years. Diabetes Obes. Metab., 16, 124, 2013.10.1111/dom.1218723911013Search in Google Scholar

22. Yale J. et al.: Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetes Obes. Metab., 16, 1016, 2014.10.1111/dom.1234824965700Search in Google Scholar

Recommended articles from Trend MD

Plan your remote conference with Sciendo